Office of the Vice President for Research


3D-Array Technology (3DAT) logo

3D-Array Technology (3DAT)

High efficient and low cost heterogeneous catalysts

3D-Array Technology (3DAT) is developing, producing and licensing high-efficiency, low-cost heterogeneous catalysts and providing cutting-edge contract catalysis research services.

3DAT is currently focusing on developing Diesel Oxidation Catalysts (DOC) and Diesel Particulate Filters (DPF) for the multi-billion dollar global diesel engine market. The company’s first engine performance test is targeted for mid-2016.


Dr. Yanbing Guo, Co-founder/CEO 

Dr. Pu-Xian Gao, Co-founder/CTO 

See full description
Avitus Orthopaedics logo

Avitus Orthopaedics

Minimally invasive medical devices for orthopaedic surgery

Avitus™ Orthopaedics, Inc. was established in 2011 with the mission of developing new orthopaedic technologies that improve clinical outcomes while decreasing healthcare costs. The company is developing a novel surgical device that will enable surgeons to use autologous bone graft material to improve the lives of patients. Avitus is currently looking to close their Series A round.


Maxim Budyansky, CTO

Neil Shah, CEO

See full description
Azitra logo


Microbiome based therapeutics- reengineering strain of bacteria

Azitra is a preclinical company focused on microbiome-based therapeutics based on a unique technology developed at Yale. Azitra is developing a platform that consists of a safe, re- engineered strain of bacteria that is able to establish residence on human skin and secrete a therapeutic protein. Azitra addresses the high unmet need of a solution for eczema (or atopic dermatitis, AD), which affects approximately 10% children under the age of 13 and 1-2% of adults (11 million) in the US.  The market for AD products is $1-2 billion dollars.

Azitra has raised $3.9 million in dilutive and non-dilutive funding so far.


Azim Munivar, Co-founder, CEO

Travis Whitfill MPH, Co-founder, CSO

See full description
Bioarray Genetics logo

Bioarray Genetics

Breast cancer molecular test

Bioarray Genetics next generation predictive tests leverage the potential of the genomic revolution to deliver clinically actionable information that optimizes treatment planning at the beginning of the cancer patient’s journey. By moving away from the “one size fits all” approach to cancer treatment, both patients and doctors can have increased confidence in treatment decisions.


Marcia Fournier, Founder & CEO



See full description
BioPharma Works (BPW) logo

BioPharma Works (BPW)

Consulting & drug discovery platform  

BioPharmaWorks, LLC (BPW), founded in 2015, is comprised of former Pfizer scientists, averaging 20+ years of R&D experience ranging from discovery to early development. BioPharmaWorks has a drug discovery portfolio, a proprietary drug combination database and does consultancy work with companies to enhance the value of their patents and products. 


Robert Volkmann

See full description
Biorasis logo


Wireless, needle-implantable biosensor for metabolism

OSCI/Biorasis was formed by Professors Faquir Jain and Fotios Papadimitrakopoulos to commercialize a minimally- invasive glucose and bio-analyte biosensor for use in drug development and eventually in human on-demand metabolic disease management. Biorasis Inc. is currently targeting the drug development and immune suppression/control markets and has a long-term goal of targeting the clinical market.


Ilze Krisst, COO

Faquir Jain, Co-Founder

Fotios Papadimitrakopulos, Co- Founder

See full description
CaroGen Corporation logo

CaroGen Corporation

Virus like vesicles technology that can be exploited to generate safe and potent vaccines

CaroGen Corporation has developed transformative virus-like vesicles (VLVs) technology that can be exploited to generate safe but potent vaccines to treat various diseases. The technology was developed by Yale Professor John Rose and has been validated in proof-of-concept studies. CaroGen is currently raising between $7 to $10 million to prepare for and complete a Phase I human clinical trial of its hepatitis B vaccine (HBV) using this technology as well as proof-of-concept in animal models for additional disease targets.


Bijan Almassian, Co-Founder/CEO

Valerian Nakaar, Co-Founder/VP

See full description
Connecticut Children's Medical Center Innovation Center logo

Connecticut Children's Medical Center Innovation Center

CCMC labs includes projects for commercialization.  
Learn more at:

Medical Device for Esophageal Defects

The technology we are presenting is an all-in-one medical device to treat esophageal defects, diseases or injuries. This device encompasses 3 different medical devices or procedures that are routinely performed in the clinical setting now, but are usually performed individually requiring the patient to undergo multiple procedures. When an esophageal stent or dilator needs to be replaced with a larger or smaller diameter additional procedures are required and this device would prevent that. Most importantly, this device also allows for localized delivery of drugs to a specific region of the esophagus, which is not an option with current medical devices.


Todd J. Jensen, MHS  | Research Associate II

Department of Pediatrics | UConn Health 

CT Children’s Medical Center Research 


Bio-Photonics Laboratory 

The technology and research efforts of Bio-Photonics Laboratory of Connecticut Children’s Innovation Center focusses on development and deployment of novel biophotonic technologies that interface and bridge spectroscopy, clinical diagnostics and label-free imaging. Specifically, they seek to employ Raman spectroscopic and imaging techniques to obtain biochemical signatures that can reveal latent information on pathological conditions. Their long-term goal is to develop and eventually deploy molecular imaging strategies to help clinicians in early disease diagnosis and biomarker identification. A principal thrust in their current research is focused in the area of pediatric hematology-oncology where they intend to develop non-invasive and label-free tool to provide biochemical insight thereby improving diagnostic and prognostic decisions.

Dr. Rishikesh Pandey

See full description
Cornovus Pharmaceuticals logo

Cornovus Pharmaceuticals

A new target and class of agents to treat cardiac failure

Cornovus Pharmaceuticals, Inc. commenced operations in October of 2011.  The company is focused on the development of a novel cardioprotective compound, MRS2339, for the treatment of heart failure.  MRS2339 was first synthesized at the NIH and is a small molecule that stimulates cardiac myocyte P2X4 receptors, which in turn can activate physically associated eNOS without a rise in intracellular calcium.  Recent data has shown that MRS2339 also increases myocyte cGMP in a heart failure model, which likely reflects a consequence of elevated nitric oxide levels.


Bruce Liang, Founder
Glenn Mattes, CEO
Mark van Allen, COO

See full description
Diameter Health logo

Diameter Health

Analytic solutions to help healthcare providers optimize patient care

Diameter Health leverages clinical data to create data- intelligent, targeted and cost effective analytic solutions to help health providers optimize patient care and operational performance. This clinical intelligence enables them to improve healthcare quality and efficiency by forecasting patient outcomes, avoiding penalties and providing insight for clinical documentation.


Eric Rosow, CEO
John D’Amore, Founder & CTO

Media Links

Video library online: 

“Taming Clinical Data Across the Care Continuum” explains how Diameter Health cures “Clinical Data Disorder” by standardizing, normalizing, de-duplicating and enriching clinical data so that it may be used for effective analytics and population health.


“Kansas Health Information Network- Diameter Health partnership” Customer testimonial with our client, Laura McCrary, Executive Director from KHIN and John D’Amore, Diameter Health’s President and Chief Strategy Officer
See full description
Dura Biotech logo

Dura Biotech

Transcatheter heart valve - smaller and more durable

DuraBiotech has patented heart valve design technology developed at UConn that improves transcatheter heart valve durability. The company’s world leading platform technologies on heart valve computer modeling and design have resulted in innovative heart valve device designs and treatment strategies for high-risk patients with severe aortic stenosis and mitral regurgitation, as well as for pediatric patients who have congenital pulmonary anomalies. Our products feature effective and durable devices, safer and easier delivery procedure, and reduced operating and post-operative recovery time.


Wei Sun, Founder & CSO

Thuy Pham, CTO  

See full description
Frequency Therapeutics logo

Frequency Therapeutics

Discoveries in stem cell biology- hearing loss

Frequency Therapeutics is a platform technology that is based on discoveries in stem cell biology made at MIT. Their initial focus is on chronic hearing loss, a potential $20B+ US market with no effective therapeutic solution. Other potential applications include gastrointestinal diseases, ocular, and diabetes.


Will McLean, Co-Founder & CSO

See full description
Health eSense logo

Health eSense

Hand held device to detect and monitor status of chronic illnesses through analysis of exhaled breath

Health eSense was founded to create a hand held, clinically accurate, non-invasive device to detect and monitor the status of chronic illnesses through analysis of exhaled breath.  This product, a breathalyzer, will empower individuals to take control of their health, leading to improved outcomes and quality of life as well as reduction in healthcare costs.

Health eSense’s initial target is kidney disease which impacts more than 20 million Americans and costs almost $50 billion annually.  Most of those with early stage kidney disease do not know it.  There is no cure for kidney failure but, if chronic kidney disease (CKD) is detected early, lifestyle changes can delay disease progression.


Claire Leonardi, CEO

See full description
HiFunda logo


See Solution Spray -precursor plasma spray coating technology for gas turbines and other applications

HiFunda is currently working with UConn to develop and commercialize a novel solution precursor plasma spray (SPPS) coating technology for gas turbines and other applications. 

Thermal energy is the most dominant source of energy used around the world for electricity generation, with greater installed capacity than any other source of energy globally. When turbines are able to operate successfully at higher temperatures, they are more energy and cost efficient. Through an ongoing US Department of Energy funded project, HiFunda and UConn are developing a new thermal barrier coating (TBC) that can operate at surface temperatures of 1300 degrees C or higher. This new technology can be a game-changer in the gas turbine industry and can help to achieve higher turbine efficiencies and therefore lower fuel consumption.

Its long term vision is to be a technology leader in the field of ceramic coating technology, and to offer commercial coating services as part of the manufacturing processes for a variety of value added industrial products.


Balakrishnan Nair, CEO

See full description
ImStem Biotechnology logo

ImStem Biotechnology

Human Mesenchymal Stem Cells (T-MSC™) for treatment of autoimmune disease

ImStem Biotechnology, Inc. (abbreviated ImStem), is a biotech company, incorporated and operating in Connecticut. ImStem is focusing on developing off-shelf cell therapeutic product derived from human pluripotent stem cells for tissue repair, cancer and autoimmune diseases treatment. With $1.13 million support from Connecticut Regenerative Medicine Research Fund, our first product IMS001 targeting multiple sclerosis has passed pre-IND meeting phase with FDA, an IND filing is anticipated for 2017. 


Xiaofang Wang, VP/CTO

Michael Men, President/CEO

See full description
InnovationCooperative 3D logo

InnovationCooperative 3D

IC3D has a platform for Measured Liquid Dispensing (metered dosing in an airless fluid dispenser for flexible packaging) that can be sold in most categories of liquid dispensing ($100B market).

InnovationCooperative3D (IC3D) was formed to leverage our collective strategic, creative and technical know-how and global relationships in package design, development, and flexible film manufacturing.

IC3D’s - 1TOUCH Measured Dispenser is the future of dispensing. 1TOUCH can dispense wide range of liquids and gels. It has superior performance, marketplace disruption and is brand-owner desired.

IC3D has 1 Utility patent issued and 2 patent pending and plans to continue investing in IP to expand the 1TOUCH measured technology’s reach. 


Roger LaFlamme, Co-Founder and CEO

See full description
LambdaVision Incorporated (LVI) logo

LambdaVision Incorporated (LVI)

Retinal implant for the blind

LambdaVision, Inc. (LVI) is developing a high-resolution, protein-based retinal implant to restore vision to the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The patent-protected retinal implant technology developed by LambdaVision uses the light-activated protein, bacteriorhodopsin, to replace the function of the damaged photoreceptor cells. The flexible, subretinal implant is powered by incident light and does not require any external power supplies or bulky hardware on or outside the eye, and offers the potential for far greater resolution than competing electrode-based technologies. LambdaVision is currently at the pre-seed stage, but is looking for seed money to support further preclinical development.


Nicole Wagner, President and CEO

See full description
Lipid Genomics logo

Lipid Genomics

Novel diagnostics and therapeutics for people with genetic cholesterol disorders at risk for heart disease

Lipid Genomics is developing its FDA-approved investigational drug targeted at people with variations in the HDL ("good cholesterol") SCARB1 gene. More than 117 million people in the US could benefit from this drug. Lipid Genomics has a potential to generate a very sizeable profit as the market size for this therapeutic is $2.8 billion and for their second product, a novel immune checkpoint inhibitor, lymphocyte activation gene-3 (LAG-3) the market size is $1.4 billion.


Annabelle Rodriguez-Oquendo, Ph.D./ Founder

Mr. Gerard C. Smith, CEO

See full description
Mattershift logo


Carbon nanotube membranes for desalination and water treatment

Mattershift is developing tools for molecular factories that can be used to assemble basic building blocks of matter into high value products. This includes for example, converting CO2 from the air into fuels, fertilizers, food, pharmaceuticals, and construction materials, without using fossil fuels as inputs. The company has completed development of its programmable molecular gateway technology with third party verification of its performance. Production is now being carried out at pilot scale.


Robert McGinnis, CEO/Founder 

See full description
MediSynergics logo


Drug discovery process

MediSynergics, LLC is an early-stage pharmaceutical research company that is working on the discovery of new treatments for patients with inadequate or unmet medical needs.  The primary mission of the company to discover new chemical entities (NCE’s) for the treatment of human diseases.   The company has discovered several “hits” in the central nervous system CNS), infectious diseases (ID) and cancer therapeutics areas and have filed provisional and non-provisional patent applications with the US Patent and Trademark Office.  Most importantly MediSynergics was awarded a two-year grant ($600K) by the NIAID division of the National Institutes for Health to fund their antiparasitic project.


Dennis Godek, Co-Founder

Harry Howard, Co-Founder

See full description
Mitotherapeutix logo


Development of agonists and antagonists of MCJ, molecule for mitochondria respiration

Mitotherapeutix aims to develop novel therapeutics based on new discoveries in the control of cellular metabolism particularly in key mitochondria regulators. One of the targets that Mitotherapeutix is currently pursuing is MCJ, a key regulator of mitochondria respiration. Mitotherapeutix is actively working in the development of agonists for this molecule to overcome chemo-resistance in breast cancer and many other cancers that demonstrate a poor response to chemotherapy. In parallel, Mitotherapeutix has developed antagonists of MCJ to accelerate mitochondrial metabolism as a strategy to target liver diseases such NAFLD, NASH and cirrhosis. Both cancer chemo-resistance and liver diseases represent enormous unmet medical needs that desperately need solutions.


Bob Hennessey, CEO

Bob Hemley, COO 

See full description
Mobile Sense Technologies logo

Mobile Sense Technologies

Mobile sensors to detect heart irregularities

Mobile Sense is building foundational technology enabling off-the-chest wearables for long term management of cardiac arrhythmias. We are replacing today’s invasive and inconvenient cardiac monitoring technology—cables & patches everywhere!— with a simple, easy to use & clinically-proven armband. Our device is non-adhesive, wireless, waterproof and provides hassle-free clinical monitoring 24/7, 365 days/yr. Neither surgery nor wires are needed to continuously detect and report dangerous arrhythmias to the doctor. Major device manufacturers are embedding our technology.


Justin Chickles, CEO

See full description
Nervomatrix logo


Hyperstimulation device for treating patients with back and neck pain.

Nervomatrix was founded in 2007 by a group of healthcare professionals and engineers who developed Soleve®, its proprietary technology and made it available for patients and clinicians. Soleve®, an FDA cleared, and CE marked, medical device, is new modality for treating patients with back and neck pain. Following its market introduction in 2012, with over 11,000 patients treated in over 40 clinical centers, Soleve® Targeted Hyper-Stimulation technique, proves to be the most innovative and superior, drug-free modality for back and neck pain relief.

The company operates in the United States, Germany and other European countries through its fully owned subsidiaries. 


Kobi Benita, VP Global Sales & Marketing

See full description
Oral Fluid Dynamics logo

Oral Fluid Dynamics

Dental implant medical device to treat chronic dry mouth

Oral Fluid Dynamics, LLC is currently developing a type of dental implant medical device to treat Xerostomia, a medical condition characterized by chronic dry mouth. Xerostomia affects an estimated 20 million patients in the USA either due to side effects of prescription drugs, radiation therapy or Sjögren’s Syndrome. There are 4 million Sjögren’s patients in the US and this population is the initial focus of our efforts.


J. Robert Kelly, Managing Partner, CEO

See full description
Potentiometric Probes, LLC logo

Potentiometric Probes, LLC

Potentiometric Probes LLC

Dyes that are both fast and sensitive for high-throughput screening of potential therapeutic targets.  The dyes use a novel VSD system where energy transfer is more efficient, resulting in faster, more sensitive, and less toxic dyes.


Potentiometric Probes develops and supplies voltage-sensitive dyes for academic and pharmaceutical industry researchers. These fluorescent dyes are used to stain cells, tissues, and whole organs and allow electrical activity of the brain and heart to be studied optically using microscopes. Voltage-sensitive dyes are used in basic research, as well as for drug discovery and cardiac safety screening of developmental drugs. Potentiometric Probes is developing new voltage-sensitive dye technology that promises to have rapid response as well as high sensitivity for the highest resolution and most informative optical voltage recordings possible.



Leslie Loew, PhD., Founding Member

Corey Acker, PhD., Founding Member

Ping Yan, PhD., Founding Member

See full description
Quercus Molecular Design, LLC logo

Quercus Molecular Design, LLC

Provides services to lower barriers to commercialization of academic discoveries in drug design.

Quercus Molecular Design (QMD) is a UConn-based startup specializing in the rational design of small molecules that simultaneously inhibit multiple essential protein targets to enhance potency and slow the onset of drug resistance. QMD is applying this novel multi-targeting strategy to several drug discovery projects serving anti-cancer, anti-bacteria and anti-viral indications.


Dennis Wright, PhD., Director of Chemistry,

Sandra Weller, PhD., Director of Biology,

Bradford Weller, JD., CEO & General Counsel,

See full description
ReinEsse LLC logo

ReinEsse LLC

Products and services to solve human skin problems

Reinesse LLC is developing products and services to solve human skin problems including wrinkles. The first product, Teeny, is focusing on improving the effectiveness of wrinkle reduction using bio-friendly nanotechnology.

Ying Liu, CEO & Founder

See full description
Shoreline Biome logo

Shoreline Biome

DNA sequencing assay to identify constituents of the microbiome of species from complex samples

Shoreline Biome has created discovery tools that are advancing the leading edge of understanding how the human microbiome functions across the entire landscape of human health and disease.  The initial products from Shoreline Biome, developed in collaboration with George Weinstock at the Jackson Lab for Genomic Medicine, are the first DNA sequencing assays to comprehensively, rapidly, and inexpensively identify all members of the microbiome down to the subspecies or strain level.  These results are achieved through our superior cell breaking technology and rational product design. Our companion analysis software enables straightforward identification and quantitation of all of the bacteria in microbiome samples.  


Thomas Jarvie, Co-Founder & CEO

Mark Driscoll, Co-Founder & CTO

See full description
Solution Spray Technologies logo

Solution Spray Technologies

Commercializes new plasma spray technologies

Solution Spray Technologies was founded through the collaboration of UConn faculty members Professors Eric Jordan and Maurice Gell with another TIP Company. The company has an exclusive license to innovative UConn solution precursor plasma spray technology (SPPS) that leverages two decades of R&D at UConn. SPPS technology provides high-value coatings solutions to address several major industrial problems and challenges. The size of the global thermal spray coating market was estimated at 7.41 billion in 2014.


Balakrishnan Nair, President


See full description
Thetis Pharmaceuticals LLC logo

Thetis Pharmaceuticals LLC

Drug for liver disease?

Thetis Pharmaceuticals LLC is a biopharmaceutical company that is developing novel drugs for treatment of inflammation-related gastrointestinal (GI) diseases with high unmet medical needs. 

Our lead candidate, TP-252, is rapidly advancing through pre-clinical evaluations in order to file an Investigational New Drug (IND) application with FDA in early 2018 to begin clinical studies soon afterward.

Our goal is to partner to license or sell TP-252 to a larger pharmaceutical company to bring the product to market, with a target market approval date of 2023.


Gary Mathias, CEO 
Aaron Mathias, Director of Business Development 

See full description
Torigen Pharmaceuticals Inc. logo

Torigen Pharmaceuticals Inc.

Provides veterinary cancer care solutions for companion animals

Torigen Pharmaceuticals, Inc. is focused on providing veterinary cancer solutions for companion animals.  Their product, VetiVax(TM) is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight cancer.   When combined with an innovative bulking agent, MIMTM (Matrix Immune Modulator) an overall reduction in tumor size and inhibition of metastasis have been noted.   Torigen’s treatment can work for multiple tumor indications treating over 2,000,000 companion animals diagnosed with cancer each year.  After completing an initial Phase I safety trial, VetiVax(TM) has been proven safe and veterinarians believe that this product could truly disrupt the market while helping animals with cancer.


Ashley Kalinauskas, CEO

See full description